Understanding the Benefits of Enasidenib 50 mg for AML Treatment in India - Delhi

Friday, 29 March, 2024

Item details

City: Delhi
Offer type: Offer

Contacts

Contact name impomed healthcare
Phone 09007090388

Item description

Enasidenib represents a significant milestone in the realm of cancer therapy, offering new possibilities for patients with relapsed or refractory AML. Clinical trials have demonstrated the remarkable efficacy of this tablet in the treatment of relapsed or refractory AML with an IDH2 mutation. It operates on a more precise level, targeting specific mutations in cancer cells.Patients receiving it experienced higher rates of complete remission compared to conventional chemotherapy, with some achieving durable responses. With the approval of Enasidenib 50/100 mg in India by regulatory authorities, including the Drug Controller General of India (DCGI), patients now have access to this cutting-edge treatment option. Impomed Healthcare provides this as a valuable treatment option to their patients to fight against leukemia.